Effect of Statin Therapy on Inflammatory Markers in HIV-Infected Patients on ART

Twenty-four weeks of rosuvastatin was associated with a significant decrease in one marker of vascular inflammation but showed no effect on other measured biomarkers.

Ongoing inflammation could help to explain the increased cardiovascular disease (CVD) risk seen among HIV-infected patients despite suppressive antiretroviral therapy (ART). The SATURN Study was designed to evaluate the effects of rosuvastatin on cardiovascular risk in patients taking ART (NEJM JW AIDS Clin Care Jan 7 2014). Eligibility criteria included stable ART (≥12 weeks), a fasting LDL cholesterol level ≤130 mg/dL, and an elevated marker of immune activation.

Of 202 patients screened, 72 were randomized to receive oral rosuvastatin (10 mg/day) and 75 to placebo. (All study drugs were manufacturer donated.) Baseline characteristics were similar between groups — for example, median age, 46 and 47; male sex, 81% and 76%; black race, 71% a…

Reviewing Author

Keith Henry, MD

Disclosures

Consultant/Advisory BoardViiV Advisory Board

Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes

Keith Henry, MD

Disclosures

Consultant/Advisory BoardViiV Advisory Board

Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes

Effect of Statin Therapy on Inflammatory Markers in HIV-Infected Patients on ART

Topics

Reviewing Author